Del Rosso A, Distler O, Milia A F, Emanueli C, Ibba-Manneschi L, Guiducci S, Conforti M L, Generini S, Pignone A, Gay S, Madeddu P, Matucci-Cerinic M
Department of Medicine, Division of Rheumatology, University of Florence, Viale G Pieraccini, 18-50139 Florence, Italy.
Ann Rheum Dis. 2005 Mar;64(3):382-7. doi: 10.1136/ard.2004.023382.
In systemic sclerosis (SSc) the lack of an angiogenic response to hypoxia may be due to inappropriate synthesis of angiogenic and angiostatic factors. Tissue kallikrein (t-kallikrein), regulating the kallikrein-kinin system and acting on the microcirculation, is a potent angiogenic agent, and kallistatin is its natural inhibitor.
To evaluate, in patients with SSc, t-kallikrein and kallistatin levels and their correlation with clinical features and measures of microvascular involvement.
Serum levels of t-kallikrein and kallistatin (ELISA) and t-kallikrein skin expression (immunohistochemistry) were studied in patients with SSc, and evaluated for subset (dSSc or lSSc), clinical and immunological features, and microvascular involvement (ulcers, telangiectasias, nailfold videocapillaroscopy).
Circulating levels of t-kallikrein were higher in SSc than in controls (p<0.001). T-kallikrein did not differ between lSSc and dSSc, although it was higher in lSSc than in controls (p<0.001).T-kallikrein levels were higher in patients with early and active capillaroscopic pattern than in those with late pattern (p = 0.019 and 0.023). Patients with giant capillaries and capillary microhaemorrhages had higher t-kallikrein concentrations than patients with architectural derangement (p = 0.04). No differences in kallistatin levels were detected between patients with SSc and controls, or between lSSc and dSSc. In early SSc skin, the presence of t-kallikrein was found in endothelial and in perivascular inflammatory cells, while no staining in skin of advanced SSc was detected.
T-kallikrein levels are increased in patients with SSc, particularly in lSSc, and are associated with early and active capillaroscopic patterns. T-kallikrein may play a part in SSc microvascular changes.
在系统性硬化症(SSc)中,对缺氧缺乏血管生成反应可能是由于血管生成因子和血管抑制因子合成不当所致。组织激肽释放酶(t - 激肽释放酶)可调节激肽释放酶 - 激肽系统并作用于微循环,是一种有效的血管生成剂,而激肽释放酶抑制蛋白是其天然抑制剂。
评估系统性硬化症患者的t - 激肽释放酶和激肽释放酶抑制蛋白水平及其与临床特征和微血管受累指标的相关性。
对系统性硬化症患者的血清t - 激肽释放酶和激肽释放酶抑制蛋白水平(酶联免疫吸附测定法)以及t - 激肽释放酶的皮肤表达(免疫组织化学法)进行研究,并根据亚型(弥漫性皮肤型系统性硬化症或局限性皮肤型系统性硬化症)、临床和免疫学特征以及微血管受累情况(溃疡、毛细血管扩张、甲襞视频毛细血管镜检查)进行评估。
系统性硬化症患者的循环t - 激肽释放酶水平高于对照组(p<0.001)。局限性皮肤型系统性硬化症和弥漫性皮肤型系统性硬化症患者的t - 激肽释放酶水平无差异,尽管局限性皮肤型系统性硬化症患者的该水平高于对照组(p<0.001)。早期和活动期毛细血管镜表现的患者t - 激肽释放酶水平高于晚期表现的患者(p = 0.019和0.023)。有巨大毛细血管和毛细血管微出血的患者t - 激肽释放酶浓度高于有血管结构紊乱的患者(p = 0.04)。系统性硬化症患者与对照组之间以及局限性皮肤型系统性硬化症和弥漫性皮肤型系统性硬化症患者之间的激肽释放酶抑制蛋白水平均未检测到差异。在早期系统性硬化症皮肤中,在内皮细胞和血管周围炎症细胞中发现了t - 激肽释放酶的存在,而在晚期系统性硬化症皮肤中未检测到染色。
系统性硬化症患者的t - 激肽释放酶水平升高,尤其是在局限性皮肤型系统性硬化症中,并且与早期和活动期毛细血管镜表现相关。t - 激肽释放酶可能在系统性硬化症微血管变化中起作用。